PDF: Update on Drugs & Devices: March-April 2022

PDF Download: This update covers Adalimumab biosimilar – Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar – Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet – Cibinqo® (Pfizer), Upadacitinib tablet – Rinvoq® (AbbVie), Risankizumab-rzaa SC injection – Skyrizi® (AbbVie), and HA-based dermal filler – Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).